Brain Reaction to Treatment of Nicotine Dependence

This study has been completed.

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00108173

Purpose

The purpose of the study is to determine how the treatments for cigarette craving work.

Hypothesis: During exposure to cigarette-related cues, heavy smokers will have greater reductions in regional brain activation from before to after both forms of active treatments than from before to after placebo.

Condition	Intervention	Phase
Nicotine Dependence	Drug: Zyban	Phase I

Drug Information available for: Bupropion hydrochloride Bupropion Nicotine polacrilex Nicotine tartrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Pharmacokinetics/Dynamics Study
Official Title:	Neural Substrates of Treatment for Nicotine Dependence

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 2002
Estimated Study Completion Date:	September 2005

Eligibility

Ages Eligible for Study:	21 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Heavy smoker, more than one pack per day
Free of medical conditions or medications that affect brain activity
Not pregnant

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00108173

Locations

United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073

Sponsors and Collaborators

Department of Veterans Affairs

More Information

Study ID Numbers:	ADRD-018-02S
Study First Received:	April 14, 2005
Last Updated:	March 27, 2008
ClinicalTrials.gov Identifier:	NCT00108173
Health Authority:	United States: Federal Government

Keywords provided by Department of Veterans Affairs:

Nicotine dependence
Position Emission Tomography (PET)
drug craving
practical group counseling

Study placed in the following topic categories:

Nicotine polacrilex
Nicotine
Mental Disorders
Tobacco Use Disorder

Bupropion
Substance-Related Disorders
Disorders of Environmental Origin

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Agonists
Autonomic Agents
Nicotinic Agonists

Physiological Effects of Drugs
Ganglionic Stimulants
Peripheral Nervous System Agents
Cholinergic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009